Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

CD3 announces fund for drug development
December 2016
SHARING OPTIONS:

LEUVEN, Belgium—In an effort to turn research into reality, the Centre for Drug Design & Discovery (CD3) has established a €60-million fund provided jointly by KU Leuven Research & Development and the European Investment Fund. The new fund will enable CD3 to move drug candidates into clinical development on its own and together with industrial partners. CD3 works to provide expert drug discovery capabilities and financial means to academic research groups and small companies to discover innovative small-molecule drugs.
 
“With this new fund, we can now build on our initial successes and further dig into new unexplored avenues for the discovery of new medicines that address some of the most serious medical needs of our time. We are delighted that the European Investment Fund and KU Leuven Research & Development offer us the support and financial means to broaden our scope and to extend our capabilities,” remarked Dr. Patrick Chaltin, managing director of CD3.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.